PAX5, a master regulator of B-cell development, was recently shown to be involved in several leukemia-associated rearrangements, which result in fusion genes encoding chimeric proteins that antagonize PAX5 transcriptional activity. In a population-based fluorescence in situ hybridization screening study of 446 childhood acute lymphoblastic leukemia (ALL) patients, we now show that PAX5 rearrangements occur at an incidence of about 2.5% of B-cell precursor ALL. Identification of several novel PAX5 partner genes, including POM121, BRD1, DACH1, HIPK1 and JAK2 brings the number of distinct PAX5 inframe fusions to at least 12. Our data show that these not only comprise transcription factors but also structural proteins and genes involved in signal transduction, which at least in part have not been implicated in tumorigenesis.
Introduction
The transcription factor Pax5 encodes the B-cell lineage-specific activator protein (BSAP) and is a master regulator of B-cell development. Within the hematopoietic system, Pax5 is exclusively expressed in the B-lymphoid lineage and is required for progression beyond the pro-B-cell stage.
1 Pax5 is not only indispensable for B-lineage commitment but its continuous expression is also essential to maintain this fate. [1] [2] [3] During B-cell lineage commitment, Pax5 fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes. [4] [5] [6] Loss of Pax5 expression in pro-Bcells by conditional gene inactivation arrests B-cell development at an early pro-B-cell stage and reverts committed B-cell precursors (BCPs) with a restricted B-lymphoid potential to progenitors with self-renewal capacity and hematopoietic pluripotency. 2, 4 The restoration of Pax5 expression suppresses the multilineage potential of Pax5 À/À pro-B-cells while simultaneously promoting their differentiation to mature B-cells. 4 The essential role of Pax5 for proper B-cell development also renders PAX5, an intriguing candidate to be involved in B-cell neoplasia. The t(9;14)(p13;q32) found in a subset of B-cell nonHodgkin's lymphoma juxtaposes the intact coding sequence of PAX5 under the control of the IGH@ locus, leading to inappropriate expression of PAX5. 7, 8 Recently, it was also shown that deletion, amplification, point mutation and structural rearrangements in genes encoding regulators of B-lymphocyte development and differentiation occur in 40% of B-progenitor acute lymphoblastic leukemia (ALL). 9 Among the affected genes, PAX5 was the most frequent target of somatic mutation, being altered in about 32% of the cases. 9 In ALL, PAX5 is involved in different translocations that result in fusion genes encoding chimeric proteins with novel functions. Thus far, ETV6, 10,11 ELN, 12 FOXP1, 9 ZNF521, 9 PML, 13 AUTS2 14 and C20orf112 14 were identified as PAX5 fusion partners. In this population-based fluorescence in situ hybridization (FISH) screening study of 446 consecutive childhood ALL cases, we determined that in BCP-ALL, PAX5 rearrangements occur at an incidence of about 2.5%. The subsequent identification of the partner genes discovered five novel in-frame PAX5 fusions to HIPK1, POM121, JAK2, DACH1 and BRD1, a set of genes with diverse functions, including not only transcription factors but also structural proteins and even a tyrosine kinase.
Materials and methods

Patients
Between June 1999 and December 2007, 486 infants and children with de novo ALL were registered in the Austrian ALLBerlin-Frankfurt-Mü nster (BFM) 2000 (n ¼ 475) and Interfant-99 15 (n ¼ 11) studies. The 486 patients also include those only registered but subsequently, for various reasons, not treated accordingly. The patients comprised n ¼ 65 with T-ALL and n ¼ 414 with B-cell leukemia, including all immunophenotypes: pro-B ALL (n ¼ 20), cALL (n ¼ 268), pre-B ALL (n ¼ 118), mature ALL (n ¼ 5) and (n ¼ 3) without specific classification. Further, the study included four biphenotypic and one NK-cell leukemia, as well as two ALLs, which were not analyzed in detail. On the basis of successful routine diagnostic work-up by cytogenetics, FISH and reverse transcription (RT)-PCR approaches, the n ¼ 421 ALLs (excluding only the n ¼ 65 T-ALL cases) consisted of 126/400 (31.5%) with high hyperdiploidy (450 chromosomes), 38/400 (9.5%) with low hyperdiploidy (47-50 chromosomes), 18/400 (4.5%) with hypodiploidy (o46 chromosomes) and 113/421 (26.8%) ETV6-RUNX1, 12/418 (2.9%) TCF3-PBX1 (E2A-PBX1), 7/421 (1.7%) BCR-ABL1 and 11/421 (2.6%) MLLpositive cases. The entire patient cohort consisted of 272 male and 214 female patients, and the age distribution ranged from 0.18 to 19.3 years (median ¼ 5.6 years). Written informed consent was obtained from the patients, their parents or their legal guardians that surplus material not required for diagnostic purposes may be used for accompanying cancer research projects.
Out of these 486 patients, from 454 patients (93.4%) sufficient material for FISH analysis was available. FISH analysis was successful in 446 (98.2%) of the analyzed cases, whereas in 8 patients (1.8%) poor quality of the fixed cells and thus insufficient hybridization efficiency precluded unambiguous evaluation of the FISH pattern.
FISH approach for the detection of PAX5 rearrangements PAX5 rearrangements were detected using PAX5 flanking BAC clones RP11-12P15 and RP11-220I1 (obtained from Pieter de Jong, BACPAC Resources, Children's Hospital and Research Center Oakland, CA, USA). Direct involvement of PAX5 was verified using the exon-specific cosmids cos-hPAX5-1 (exons 2-5) and cos-hPAX5-3 (exons 9 and 10). 7 For metaphase analysis also, RP11-465P6 and RP11-84P7 were applied (obtained from M Rocchi, Department of Cytogenetics, University of Bari, Bari, Italy). Exact clone positions relative to PAX5 are illustrated in Supplementary Figure S1 .
BAC and cosmid DNA was isolated using the PSI-Clone BAC DNA Kit (emp Biotech, Berlin, Germany) and the QIAprep Spin Miniprep Kit (Qiagen, Vienna, Austria), respectively. BAC and cosmid DNA was then amplified with the TempliPhi Amplification Kit (GE Healthcare, Vienna, Austria) according to the manufacturer's recommendations. Slides for FISH were prepared from the methanol/acetic acid-fixed cell suspensions used for cytogenetic analysis and incubated in Nonidet P40 (Sigma-Aldrich, Vienna, Austria) 0.4%/2 Â SSC at 37 1C for 1 h and then immediately dehydrated through an ascending ethanol series followed by 3 min of pepsin digestion. FISH was essentially performed as described earlier. 16 Metaphase images were acquired with a Zeiss Axioplan 2 Imaging fluorescence microscope (Zeiss, Gö ttingen, Germany) equipped with appropriate filter sets using a Zeiss AxioCam MRm CCD camera and the Isis version 5.0 SR-6 FISH Imaging System (MetaSystems, Altlussheim, Germany). High-throughput automated interphase FISH spot counting was accomplished using the Axioplan 2 microscope coupled to the Metafer4-Metacyte system, version V 3.1.122 (MetaSystems). Following automated analyses of 300-400 nuclei per case, each sample was manually reevaluated. On the basis of the analysis of normal controls and leukemia samples with normal PAX5 status, separation of differentially labeled clones was considered when the distance between the signals was 410 pixel.
Identification of PAX5 fusion partners PAX5 fusion partners were identified by rapid amplification of cDNA ends (RACE) or FISH analysis.
RACE.
Total RNA was extracted from mononuclear cells isolated from bone marrow using the PeqGOLD Total RNA Kit (Peqlab Biotechnology, Erlangen, Germany), including an on column DNAse digestion step. Total RNA (300 ng-2 mg) was reverse transcribed using the AMV Reverse Transcriptase and the cDNA synthesis primer provided with the Marathon Kit (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France) followed by second-strand cDNA synthesis according to the manufacturer's instructions. Ligation of the Marathon cDNA Adaptor to the ds-cDNA was performed overnight at 16 1C. Appropriately diluted adapter-ligated ds-cDNA was amplified using the PAX5 gene-specific forward primer PAX5ex2-3-F1 (5 0 -TCTTGGCAGGTATTATGAGACAGGAAG-3 0 ) or the reverse primer PAX5ex6-7-R1 (5 0 -TGGCTGAATACTCTGTGGTCTGCT C-3 0 ) and the adaptor primer AP1 (5 0 -CCATCCTAATACGACTCA CTATAGGGC-3 0 ). A nested PCR reaction was carried out with the PAX5-specific primers PAX5ex3-F2 (5 0 -CAGAGCGGGTGT GTGACAATGAC-3 0 ) or PAX5ex6-R1 (5 0 -CTGCTGCTGTGTGAA CAAGTCTCC-3 0 ) and the AP2 (5 0 -ACTCACTATAGGGCTC GAG CGGC-3 0 ) universal primer. PCRs were carried out with a T3000 Thermocycler (Biometra, Gö ttingen, Germany) using the following cycling parameters: 95 1C initial denaturation for 1 min; RACE products were cut out from the gels, extracted using the PeqGOLD Gel Extraction Kit (Peqlab Biotechnology) and directly sequenced or cloned into the pGEM-T Easy vector (Promega, Mannheim, Germany) and sequenced. Sequencing was performed by Eurofins MWG Operon (Ebersberg, Germany).
FISH. The PAX5-C20orf112 fusion was detected using RP11-431F4 and RP11-465P6 (M Rocchi) encompassing the complete PAX5 gene (Supplementary Figure S1) in combination with RP5-1184F4 (Welcome Trust Sanger Institute; http://www. sanger.ac.uk), which spans the C20orf112 locus. Amplification of full-length PAX5 fusion transcripts was accomplished either in one round or in two consecutive nested PCR reactions with Finnzymes Phusion Hot Start High-Fidelity DNA Polymerase (Biozym Scientific GmbH, Vienna, Austria). All primer sequences and the combinations used are provided in Supplementary Table S1 . PCR products were either cut out from the gels and extracted with the PeqGOLD Gel Extraction Kit (Peqlab Biotechnology) or directly purified using the QiaQuick PCR Purification Kit (Qiagen) and sequenced by Eurofins MWG Operon.
RT-PCR analysis
Western blotting
Appropriate material for western blot analysis was only available from one case with a PAX5 rearrangement. The KIS-1 cell line served as PAX5 wild-type positive control. Protein was extracted with standard lyses buffer in the presence of protease inhibitor (Roche Diagnostics GmbH, Vienna, Austria). Total proteins were separated by SDS-polyacrylamide gel electrophoresis on NuPAGE 4-12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membrane using the XCell SureLock and the XCell II Blot module (Invitrogen) according to the manufacturer's instructions. After blocking with blocking reagent (Roche), membranes were incubated with an anti-Nterminal PAX5 antibody (ab12000; Abcam, Cambridge, UK). Following incubation with a secondary antibody, bands were visualized using the LI-COR Odyssey system (LI-COR Biosciences GmbH, Bad Homburg, Germany). Membranes were stripped with 1% SDS and 25 mM glycine pH 2 and reincubated with anti-GAPDH antibody (6C5; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and an appropriate secondary antibody.
Gene and exon nomenclature
The gene nomenclature throughout this paper follows that approved by the Human Genome Nomenclature Committee (HUGO) (http://www.genenames.org/). Nucleotide reference sequences used for primer design and the description of the novel PAX5 partner genes were the following: PAX5, NM_016734; HIPK1, NM_198268; POM121, NM_172020 and OTTHUMT00000252020 POM121-001 (the reference sequence differs from the latter by lack of exon 4 described in Ensembl and the sequences have alternative 3 0 -ends); JAK2, NM_004972; DACH1, NM_080759; BRD1, NM_014577; C20orf112, NM_080616; (National Center of Biotechnology Information (NCBI)).
Results
FISH screening for PAX5 rearrangements
Interphase FISH analysis of 446 childhood ALL samples detected FISH patterns suggestive of PAX5 rearrangements in 10 cases. PAX5 rearrangements were exclusively found in BCP-ALL, and thus, the overall frequency in childhood ALL was 2.2%, whereas the incidence in BCP-ALL was 2.6%.
In seven cases (1.6%), the dual-color split-apart assay with PAX5-flanking BAC clones detected a separation of the signals, suggesting the presence of a PAX5 rearrangement. In 5 cases (1.1%), deletions of the 3 0 clone and in 15 cases (3.4%), deletions of the 5 0 clone were observed. One single case displayed an additional 3 0 signal and further analysis confirmed a duplication encompassing the PAX5 3 0 -end and flanking sequences.
All aberrant cases were further analyzed using PAX5 genespecific cosmids, which proved the direct involvement of PAX5 in all seven cases showing a split FISH pattern with the BAC clones. Out of the 15 cases with a 5 0 BAC clone deletion, 8 were ETV6-RUNX1 positive and were not further analyzed. One case was not analyzable, three displayed no PAX5 aberration and three a 5 0 deletion, suggesting focal PAX5 deletions. 9 In two out of the five cases with a 3 0 BAC clone deletion, one entire copy of PAX5 was absent, whereas in three cases a 3 0 internal deletion was confirmed, indicating a PAX5 fusion associated with a 3 0 deletion.
Identification of PAX5 fusion partners
In all 10 cases that displayed a FISH pattern suggestive of the presence of a PAX5 fusion (Table 1) , we attempted to identify the respective partner gene. In two of the cases, one each with a split FISH pattern and a PAX5 3 0 deletion we have earlier identified PML 13 (case 1) and ETV6 11 (case 9) as fusion partners, respectively (Table 1) . To determine whether in any of the cases one of the known PAX5 partners was involved, PAX5 fusion gene-specific FISH and/or RT-PCR experiments were performed first, and as soon as we were able to unravel a novel fusion partner all cases were retrospectively analyzed.
Identification of PAX5 fusion partners in PAX5-rearranged leukemia
In cases 2 and 4, only a minor but significant percentage of the cells (20.8 and 19 .3%) displayed a split FISH signal pattern (Table 1) . Subsequent evaluation of metaphases clearly showed that the PAX5-flanking probes were separated and both were located on chromosome 9p, suggesting an inversion event (Figure 1a) . 3 0 RACE using RNA isolated from the bone marrow obtained at relapse of case 4 resulted in an approximately 2 kb amplification product (data not shown) and sequence analysis revealed fusion of PAX5 exon 5 with JAK2 exon 19 ( Figure 1d) . RT-PCR analysis of the diagnostic samples of both cases confirmed the presence of the same PAX5-JAK2 transcripts (Figure 1b) . Amplification of the reciprocal JAK2-PAX5 fusion showed multiple splice variants that either included all respective JAK2 exons or lacked exon 18 or exons 17 and 18 (Figures 1c and e) . The splice variant containing all JAK2 exons and that lacking exons 17 and 18 resulted in open reading frames. Using primers in the respective first and last coding exons, both PAX5-JAK2 and JAK2-PAX5 full-length transcripts could be amplified, which apart from the splice variants described above did not lack any other exons (Figures 3a and b, and data not shown). Western blot analysis revealed expression of the predicted size mutant PAX5 protein as well as wild-type PAX5 (Figure 3d ).
The putative PAX5-JAK2 chimeric protein contains the paired domain (PD) and the octapeptide domain of PAX5 (Figure 4a ) and the JAK homology (JH) 1 kinase domain of JAK2. The fulllength hypothetical reciprocal JAK2-PAX5 fusion protein consists of the JAK2 kinase domains JH2-JH7 fused to the PAX5 homeodomain (HD) and the transactivation and inhibitory domains (Figure 4b ). The shorter JAK2-PAX5 in-frame isoform would lack the JH2 domain.
In case 3, 3 0 RACE and direct sequencing of a PCR product revealed fusion of PAX5 exon 5 with the non-coding region of BRD1 exon 1. Subsequent fusion gene-specific RT-PCR verified the data obtained by RACE (Figure 2a ). PAX5 exon 5 was joined to 14 bp of the non-coding exon 1 of BRD1, resulting in a putative chimeric protein consisting of the PAX5 PD and the octapeptide domain fused to four miscellaneous amino acids and the entire BRD1 protein, which contains highly conserved domains, such as an amino-terminal plant HD (PHD) zinc-finger and a bromodomain (Figure 4c ). Insufficiency of material prevented amplification of the full-length fusion transcript, the coding region of which would have an estimated length of 3795 bp.
In case 5, FISH analysis clearly showed a PAX5 rearrangement (Figure 2bi and ii), but 3 0 RACE failed to identify the PAX5 fusion PAX5 fusion genes in childhood ALL K Nebral et al partner. However, cloning and sequencing of 5 0 RACE products revealed that one clone encompassed PAX5 exon 6 fused to the non-coding exon 4 of POM121 (data not shown). These data prompted us to perform PAX5-POM121-specific RT-PCR experiments and indeed PAX5-POM121 transcripts could be amplified (Figure 2biii ). Sequence analysis showed that PAX5 exon 5 was fused to 112 bp of genomic DNA derived from chromosome 12 followed by POM121 exon 5 (Figure 2b) , suggesting a complex rearrangement between chromosomes 7, 9 and 12. Exons 1-4 of POM121 are non-coding and the translational start codon is located in exon 5. Nevertheless the insertion of the 112 bp genomic DNA resulted in a complete open reading frame and a putative fusion protein consisting of the PD and the octapeptide domain of PAX5 joined to 88 amino acids neither homologous to PAX5 nor POM121, and the entire POM121 protein (Figure 4d ). Owing to the lack of appropriate material, the full-length coding transcript, which would have a calculated size of 3867 bp, could not be amplified, and thus, it remains elusive whether all exons are retained or different splice variants of PAX5-POM121 are expressed.
In case 6, FISH experiments showed that the 5 0 -end of PAX5 was located on a der(9) chromosome, whereas the 3 0 -end was translocated to 14q32 (data not shown). Further thorough FISH analysis confirmed the presence of complex rearrangements involving at least chromosomes 9, 3, 11 and 12 with insertion of chromosome 11p material into 9p (data not shown), indicating fusion of PAX5 with a gene located on 11p. However, though 20 BAC clones, which encompassed 11p13-15 were hybridized none of them showed a colocalization with PAX5, and thus, this strategy failed to identify any candidate gene. Consequently, also in this case 3 0 and 5 0 RACE were performed, but despite extensive efforts we were unable to identify the PAX5 partner gene.
In case 7, FISH analysis showed a split signal for the PAX5-specific clones and 1-2 additional 5 0 signals (Figure 2ci ). Further FISH analysis again indicated complex aberrations involving several chromosomes, in particular 1p, which was translocated to 9p (data not shown). Cloning and sequencing of an approximately 1.8 kb 3 0 RACE product suggested the involvement of the HIPK1 gene. Fusion gene-specific RT-PCR experiments with primers located in exons 5 and 9/10 of PAX5 and HIPK1, respectively, confirmed the RACE data (Figure 2cii) . Amplification of the fusion transcript with primers located in exons 1 and 5 of PAX5 and at the junction of the last coding exons 15/16 of HIPK1 showed that PAX5 exons 1-5 were consistently present, but HIPK1 C-terminal exons were alternatively spliced, and thus, several variants are expressed (data not shown). Reciprocal HIPK1-PAX5 transcripts could not be detected.
The putative PAX5-HIPK1 chimeric protein encoded by the notional full-length transcript consists of the PD and the octapeptide domain of PAX5 fused to a part of the HD-interacting domain, the proline-, glutamic acid-, serine-, threonine-rich and the tyrosine/histidine-rich domains of HIPK1 (Figure 4e ). In 3 out of the 446 childhood ALL patients, FISH analysis with PAX5-specific cosmid clones displayed 3 0 deletions of PAX5 also, indicating the presence of PAX5 rearrangements. In this respect, the dic(9;12)/PAX5-ETV6 aberration results in loss of the PAX5 3 0 -end, 11 and the PAX5 fusion partners FOXP1, ZNF521, AUTS2 and C20orf112 were detected based on array comparative genomic hybridization data that only permit the delineation of unbalanced genetic alterations. 9, 14 In case 8, fusion gene-specific FISH and RT-PCR assays for the known PAX5 rearrangements revealed that in this case PAX5 was fused to C20orf112 14 ( Figure 2d ). Sequence analysis of the PAX5-C20orf112 transcripts showed an in-frame fusion of PAX5 exon 8 with C20orf112 exon 12. Amplification of the full-length coding chimeric transcript showed no alternative splicing of any of the exons (data not shown). At least in this case, the PAX5-C20orf112 fusion displays the most 3 0 breakpoint within PAX5 described so far, which joins almost the entire PAX5 protein, including the PD, the octapeptide, the HD and parts of the transactivation domain to the C-terminal end of C20orf112. Owing to the opposite transcriptional orientations of PAX5 (centromere-telomere) and C20orf112 (telomere-centromere), the generation of a functional fusion gene requires a complex genetic rearrangement or the formation of a dicentric chromosome.
In case 10, interphase FISH analysis showed deletion of the PAX5 3 0 -end (Figure 2ei) , and direct sequencing of one of several 3 0 RACE PCR products revealed an in-frame fusion of PAX5 exon 5 with DACH1 exon 5 (Figure 2eii ). Subsequent RT-PCR experiments using a forward primer located in exon 5 of PAX5 and a set of reverse primers in exons 5, 8, 9 and 12 of DACH1 showed the formerly described alternative splicing of DACH1 skipping exons 4, 5, 6 or 7 or a combination thereof. 17 Fusion of PAX5 with a DACH1 isoform that was only detected in spleen could not be verified. Sequencing of RT-PCR products amplified with primers located in the first and last coding exon of the respective genes consistently showed the presence of PAX5 exons 1-5 and confirmed splicing of DACH1 (Figure 3c ). Also in this case, the centromere-telomere orientation of PAX5 and the opposite telomere-centromere transcriptional direction of DACH1 suggested a more complex rearrangement rather than a simple reciprocal translocation. The PAX5-DACH1 putative consensus fusion protein consisted of the PD and the 
Discussion
Using a FISH approach for the detection of PAX5 rearrangements, we performed a population-based screening of 446 consecutive childhood ALL cases and identified 10 (2.6%) BCP-ALL patients with a PAX5 rearrangement. All PAX5 fusionpositive cases were negative for the most common genetic aberrations found in childhood ALL (ETV6-RUNX1, BCR-ABL1, TCF3-PBX1 and MLL-AF4), and thus, in contrast to PAX5 deletions, they are most likely distinctive primary genetic events. PAX5 rearrangements were particularly associated with a common ALL phenotype. Except for the PAX5-POM121-positive case, all patients showed a good response to prednisone according to the ALL-BFM 2000 or Interfant-99 15 protocol. On the basis of prednisone response and minimal residual disease risk stratification, all patients were treated with the respective therapy regimen and 9/10 patients are in first complete remission 6-84 months from diagnosis. Only one of the two PAX5-JAK2-positive patients with a pre-B phenotype relapsed 2.5 years after initial diagnosis but after recommencing therapy, the patient has achieved a second complete remission (Supplementary Table S2 ).
So far, the majority of PAX5 rearrangements was detected by high-resolution single nucleotide polymorphism array analysis, 9,14 a technology that, however, only allows for the detection of unbalanced aberrations and precludes the identification of balanced reciprocal translocations or inversions. Therefore, we took an alternative approach and developed a FISH screening assay that permits the unambiguous detection of all PAX5 rearrangements independent of their balanced or unbalanced nature, including even those that would result in juxtaposition of PAX5 under the regulatory elements of a partner gene as seen in the PAX5-IGH@ translocation. 7, 8 It is interesting to note that most PAX5 rearrangements were found in cases with either normal or complex karyotypes, a fact that prevents detection by conventional cytogenetics and emphasizes their often cryptic nature. Further, at least in childhood ALL, we did not find any evidence for PAX5 activating translocations.
In total, 2 of the 10 PAX5-rearranged cases have been reported earlier to harbor a PAX5-ETV6
11 and a PAX5-PML 13 aberration, and one showed the recently described PAX5-C20orf112 fusion. 14 However, we identified five hitherto unknown PAX5 fusion partners, namely HIPK1, POM121, JAK2, DACH1 and BRD1 bringing the number of distinct PAX5 chimera to at least 12 ( Table 2 ). Similar to all earlier described PAX5 rearrangements, the majority of the fusion transcripts encode putative novel transcription factors, which consist of at least the amino-terminal paired DNA-binding domain and in most instances also the octapeptide of PAX5, and C-terminal regulatory sequences of a second transcription factor. However, involvement of ELN and POM121 as structural proteins and the tyrosine kinase JAK2 are remarkable as neither of these genes is directly implicated in transcriptional regulation.
The Janus kinase (JAK) family currently comprises four human members JAK1, JAK2, JAK3 and TYK2, which are receptorassociated protein tyrosine kinases and are of critical importance for cytokine-mediated signal transduction. 18, 19 Somatically acquired activating mutations in JAK2 were recently reported to play a central role in the pathogenesis of myeloproliferative disorders. 20 Further, JAK2 fusions with ETV6, BCR, PCM1 and SSBP2 were described in a variety of hematopoietic malignancies. 21, 22 The transforming potential of the earlier described JAK2 fusion proteins has been attributed to the cytokine-independent constitutive activation of JAK2, mediated by motifs of the partner gene that serve as dimerization-oligomerization interfaces. 21 For example, for the three distinct ETV6-JAK2 fusions, which are potent activators of STAT5, transformation is strictly dependent on the ETV6 pointed (PNT) self-association domain. 23 However, there is no evidence that the PAX5 domains retained in the PAX5-JAK2 protein are capable of mediating dimerization. In contrast, both the DNAbinding domain and the nuclear localization signal of PAX5 24 are retained in the PAX5-JAK2 fusion protein, which is suggestive of a nuclear localization, whereas JAK2-PAX5 may reside in the cytoplasm.
BRD1, BRPF1, MLLT6 and MLLT10 belong to a small evolutionary conserved family of putative nuclear transcription factors, which share a highly homologous cystein-rich region containing an amino-terminal PHD finger motif. 25 Two members of this family are involved in myeloid leukemia-associated rearrangements, namely MLL-MLLT6 and MLL-MLLT10. 26, 27 However, the respective chimeric proteins differ considerably from PAX5-BRD1 in that the conserved PHD domains of MLLT6 and MLLT10 are lost, whereas the entire BRD1 protein is fused to PAX5. Even though the actual function of BRD1 itself remains elusive, the presence of a PHD-bromodomain module, which is frequently found in chromatin-associated proteins, strongly indicates a role in chromatin remodeling and epigenetic regulation of gene transcription. 28, 29 Considering that PAX5 has the capability to activate and suppress large sets of genes, this potential feature of BRD1 supports the notion of the PAX5-BRD1 chimera to modulate transcriptional activity.
HIPK1 belongs to the HD-interacting protein kinase (HIPK) family, which currently has four members (HIPK1-4) and they are nuclear serine/threonine kinases that are primarily localized in the nucleus. 30, 31 The HIPKs were originally identified as nuclear protein kinases that function as corepressors for various HD-containing transcription factors but were also recently shown to interact with other proteins involved in apoptosis and signal transduction in a cellular localization-dependent manner. HIPK1 physically interacts with and promotes phosphorylation of, for example, TP53, DAXX, EP300 and RUNX1. [32] [33] [34] HIPK1 also regulates the nuclear export of DAXX and both proteins collaborate in transcriptional regulation, 33 a functional aspect of HIPK1, which is further substantiated by its modulation of TP53 activity. 34 On the other hand, in the cytoplasm, HIPKs appear to transduce signals by death receptors and to induce MAP3K5-dependent apoptosis. 35, 36 Owing to the multiple functions of HIPK1 it is intricate to ascribe any potential specific function to the PAX5-HIPK1 fusion protein, however, the most likely one is also transcriptional regulation.
DACH1 is a human homolog of the Drosophila dachshund (dac) gene, which is a key regulator of cell-fate determination during eye, leg and brain development in the fly. [37] [38] [39] Members of the dachshund family of nuclear proteins encode highly conserved putative transcription factors, which contribute to the fundamental mechanisms of morphogenesis. 40, 41 The DACH1 protein contains two domains (DD1, Dachbox N-domain and DD2, Dachbox C-domain or EYA domain), which are highly conserved from Drosophila to human.
41 DACH1 functions as a transcriptional repressor of TGF-b signaling in breast and ovarian cancer. 42, 43 DACH1 is also a physiological regulator of endogenous JUN function, inhibiting JUN and JUN target gene expression, as well as a CCND1 repressor. 44 Although target gene repression by DACH1 requires the DD1 domain, it is tempting to speculate that the PAX5-DACH1 chimeric protein, in spite of the fact that it lacks this conserved domain, may act as transcriptional repressor of PAX5-activated target genes. PAX5 fusion genes in childhood ALL K Nebral et al PAX5 fusion partners, however, not only comprise transcription factors but also structural proteins such as ELN 12 and POM121. POM121 is one of the two integral pore membrane proteins that were identified as specific components of nuclear pore complexes of higher eukaryotes. 45 Both pore membrane proteins, nucleoporin (NUP) 210 46 and POM121 45 have been proposed, although controversially discussed, to play important roles in nuclear pore complex formation and anchoring the peripheral NUPs to the nuclear membrane. 47, 48 The nuclear pore complex is composed of multiple copies of about 30 different NUPs, 49 and thus far, only 2 NUPs, namely NUP98 50, 51 and NUP214, [52] [53] [54] were found involved in leukemia-associated translocations, which makes POM121 only the third component of the nuclear envelope implicated in leukemogenesis.
All PAX5 fusion proteins contain the PAX5 DNA-binding domain and thus are predicted to retain the ability to bind to PAX5 transcriptional targets, but no longer provide normal transcriptional regulatory functions.
55 PAX5-ETV6, PAX5-FOXP1 and also PAX5-ELN indeed competitively inhibit the transcriptional activity of PAX5, suggesting that PAX5 fusions act as constitutive repressors to antagonize PAX5 function provided by the second, wild-type PAX5 allele. 9, 12, 56 Comprehensive studies are now required to elucidate whether all PAX5 chimera in fact operate as aberrant transcription factors that impair the finely tuned PAX5 target gene transcriptional network.
